Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Vomiting 1Rectal Neoplasms 1Nausea 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Fluorouracil 267Oxaliplatin 266Capecitabine 225Leucovorin 209Irinotecan 151Radiotherapy 132Bevacizumab 112Cetuximab 81Folfox protocol 49Surgical Procedures, Operative 44Radiation 41Drug Therapy 41Neoadjuvant Therapy 40Chemoradiotherapy 33Chemotherapy, Adjuvant 32Panitumumab 27XELOX 25Magnetic Resonance Spectroscopy 22Radiotherapy, Intensity-Modulated 21Floxuridine 17Biopsy 16Nivolumab 15Gemcitabine 15Early Intervention, Educational 15pembrolizumab 14Laparoscopy 14IFL protocol 14Celecoxib 14trifluridine tipiracil drug combination 13Gene Expression Profiling 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Rectal Neoplasms × L 758298 × Clear all
NCT00381862 2017-06-12

Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX

OHSU Knight Cancer Institute

Phase 2 Completed
54 enrolled 7 charts
Gastrointestinal

Colonic Neoplasms, Nausea, Rectal Neoplasms, Vomiting, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡